anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Students in the control group will not be given any application. A pre-test will be administered before starting the study, an interim test will be applied 8 weeks after the pre-test, and a post-test will be applied 3 months after the interim test. After the study is over, mindfulness will be applied to the students in the control group.
Women's Interventions for Sexual Health (WISH), is a two-arm randomized clinical trial to evaluate the feasibility and acceptability of a multi-component intervention addressing changes in body image, sexual desire, and vaginal dryness in thirty adult post-treatment breast cancer survivors. The study is eight weeks long and does not require any in-person visits. If a breast cancer survivor is determined eligible, they will be educated on the purpose, requirements, and procedures. If interested, they will be emailed the consent form and will schedule a virtual consent/baseline visit. After consent is obtained, the participant will be randomly assigned to a study arm, HRI (hypnotic relaxation intervention plus vaginal moisturizer) or VVA (vulvovaginal atrophy moisturizer only), given a study number, and educated on the use of Replens™ vaginal moisturizer. The participant will complete online surveys at the virtual baseline visit. Replens™ vaginal moisturizer will be sent to the participant's address and receipt of the moisturizer will be confirmed by study staff before the agreed upon week one start date. The participant will use the moisturizer every day during weeks one and two and every other day during weeks three through eight. Participants randomized to the HRI group will also receive an MP3 player with three hypnotic relaxation audio files and asked to complete a weekly practice log. Each hypnotic induction audio file will be used for two weeks, three times per week, for a total of six weeks of hypnosis. A second virtual visit will be held at two weeks to assess progress, adverse events and provide education to the HRI group. Check in phone calls will be scheduled for weeks four, six and eight. A link to online follow up surveys will be shared during weeks six and eight.
Training two times per week. IMT with 5 rounds and 12 repetitions in each round at 60-80% MIP. The primary protocol will end at 6 weeks and the self-administered long-term protocol will end at 12 months after intervention start.
Psoriasis is a chronic, recurrent, inflammatory dermatosis accompanied by excessive activation of dendritic cells (DCs), which are primarily responsible for initiating an immune response. The bromodomain and extraterminal domain (BET) family plays a pivotal role in the transcriptional regulation of inflammation and its inhibitors can downregulate DCs maturation and activation. Here we investigated the effect of NHWD-870, a potent BET inhibitor, on inflammation in an imiquimod (IMQ)-induced psoriasis-like mouse model and murine bone marrow-derived dendritic cells (BMDCs) stimulated by lipopolysaccharide (LPS) and IMQ. Application of NHWD-870 significantly ameliorated IMQ-triggered skin inflammation in mice, and markers associated with DC maturation (CD40, CD80 and CD86) were decreased in skin lesions, spleen and lymph nodes. Additionally, NHWD-870 reduced LPS or IMQ induced DCs maturation and activation in vitro, with lower expression of inflammatory cytokines [interleukin (IL)-12, IL-23, tumor necrosis factor-α, IL-6, IL-1β, chemokine (C-X-C motif) ligand (CXCL)9 and CXCL10]. In addition, we found that interferon regulatory factor 7 (IRF7) significantly increased during DCs maturation, and inhibition of IRF7 could impair BMDCs maturation and activation. What's more, IRF7 was highly expressed in both psoriatic patients and IMQ-induced psoriasis-like mice. Single-cell RNA sequencing of normal and psoriatic skin demonstrated that IRF7 expression was increased in DCs of psoriatic skin. While NHWD-870 could inhibit IRF7 and phosphorylated-IRF7 expression in vivo and in vitro. These results indicate that NHWD-870 suppresses the maturation and activation of DCs by decreasing IRF7 proteins which finally alleviates psoriasis-like skin lesions, and NHWD-870 may be a potent therapeutic drug for psoriasis.
Spencer muscle energy technique (SMET) attempts to re-establish functional relationship between soft and articular tissues of the shoulder region, minimizes inflammatory and later developing fibrotic process, and restores arterial, venous, and lymphatic flow. Like other OMT procedures, it not only restores joint functions, but enhances positive well-being and full expression of a patient's life. In this technique, passive, smooth, rhythmic motion of the shoulder joint is done by the therapist to stretch contracted muscles, ligaments, and capsule (Babu And Putcha.,2022).
OBJECTIVE: The 2010 Pacific Vascular Symposium 6 (PVS6) brought venous disease content experts together with a goal of addressing critical issues collated together in the next decade with concrete plans to achieve these goals. This mapping review aims to provide a broader representation of how progress in critical issues of chronic venous disease has been made by extrapolating scientific publications related to the PVS6 initiatives.
METHODS: We performed a mapping review identifying original or systematic review/meta-analysis articles related to PVS 6 initiatives (aims) that addressed one of the following key objectives: scales to measure chronic venous disease, effectiveness of interventional deep venous thrombus removal, development of a deep venous valve, and biomarkers related to venous disease. Searches were undertaken in PubMed, Ovid Medline, Cochrane Library, Embase (Elsevier), CINAHL (EBSCO), and Scopus. We extracted descriptive information about the studies and predefined variables for each specific aim, showing what and where research exists on the aims included.
RESULTS: A total of 2138 articles were screened from 3379 retrieved articles from six electronic databases. We mapped 186 included articles, finding that the total number of publications significantly increased after the 2010 PVS6 meeting. Aim results were visually summarized. The largest body of data addressed catheter-based thrombus removal strategies for acute iliofemoral deep venous thrombosis. Primary research on artificial venous valves and venous biomarkers remained limited. No new post-thrombotic syndrome (PTS) score has been developed.
CONCLUSIONS: This mapping review identified and characterized the available evidence and gaps in our knowledge of chronic venous disease that exist visually, which may guide where more significant investments for the future should be targeted.
BACKGROUND: Risk stratification and treatment benefit prediction models are urgent to improve negative sentinel lymph node (SLN-) melanoma patient selection, thus avoiding costly and toxic treatments in patients at low risk of recurrence. To this end, the application of artificial intelligence (AI) could help clinicians to better calculate the recurrence risk and choose whether to perform adjuvant therapy.
METHODS: We made use of AI to predict recurrence-free status (RFS) within 2-years from diagnosis in 94 SLN- melanoma patients. In detail, we detected quantitative imaging information from H&E slides of a cohort of 71 SLN- melanoma patients, who registered at Istituto Tumori "Giovanni Paolo II" in Bari, Italy (investigational cohort, IC). For each slide, two expert pathologists firstly annotated two Regions of Interest (ROIs) containing tumor cells alone (TUMOR ROI) or with infiltrating cells (TUMOR + INF ROI). In correspondence of the two kinds of ROIs, two AI-based models were developed to extract information directly from the tiles in which each ROI was automatically divided. This information was then used to predict RFS. Performances of the models were computed according to a 5-fold cross validation scheme. We further validated the prediction power of the two models on an independent external validation cohort of 23 SLN- melanoma patients (validation cohort, VC).
RESULTS: The TUMOR ROIs have revealed more informative than the TUMOR + INF ROIs. An Area Under the Curve (AUC) value of 79.1% and 62.3%, a sensitivity value of 81.2% and 76.9%, a specificity value of 70.0% and 43.3%, an accuracy value of 73.2% and 53.4%, were achieved on the TUMOR and TUMOR + INF ROIs extracted for the IC cohort, respectively. An AUC value of 76.5% and 65.2%, a sensitivity value of 66.7% and 41.6%, a specificity value of 70.0% and 55.9%, an accuracy value of 70.0% and 56.5%, were achieved on the TUMOR and TUMOR + INF ROIs extracted for the VC cohort, respectively.
CONCLUSIONS: Our approach represents a first effort to develop a non-invasive prognostic method to better define the recurrence risk and improve the management of SLN- melanoma patients.
Hepatotoxicity, occasionally severe, may occur with imatinib [see Adverse Reactions (6.1)]. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of imatinib. Monitor liver function (transaminases, bilirubin, and alkaline phosphatase) before initiation of treatment and monthly, or as clinically indicated. Manage laboratory abnormalities with imatinib interruption and/or dose reduction [see Dosage and Administration (2.13)].When imatinib is combined with chemotherapy, liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Additionally, there have been reports of acute liver failure. Monitoring of hepatic function is recommended.
An artificial pancreas system will likely require multiple glucose sensing elements to function safely. It is not yet known how close two glucose sensors can be placed and still work properly. Meaning, if one is reading inaccurately,and the other is positioned adjacent to it, will it read inaccurately also, defeating the purpose of having two sensors. Twenty adult subjects with Type 1 diabetes will wear four Medtronic REAL-Time glucose sensors during two separate 10-hour studies. The inter-sensor distances of each pair to be tested will be: 2, 10, 20, and 30mm apart. The sensors will be inserted the day prior to the study day to allow for signal stabilization and calibration. During the study day, arterialized venous blood will be drawn every 15 minutes to measure blood glucose. The sensor values and interstitial values will be recorded from each sensor receiver at each time point. Subjects will be fed two standardized meals and given pre-meal insulin based on their typical insulin to carbohydrate ratio.
This was a multicenter, randomized, double-blind, double-dummy safety study in adult patients who required continuous opioid treatment for chronic pain. Patients had to be on a stable dose of duragesic for 21 days prior to the start of the study treatment period and have completed a screening period of at least 14 days to enter this study. Eligible patients were randomized (2:1) to receive the equivalent strength of D-TRANS fentanyl with naltrexone HCl (and placebo Duragesic) or the same dose of Duragesic (and placebo D-TRANS fentanyl with naltrexone HCl \[D-TRANS fentanyl with naltrexone\]) for a 15-day treatment period. If necessary, patients could be titrated to higher or lower doses during the 15-day treatment period. Each system was worn for 72 hours then replaced by a new system until the end of the 15-day treatment period. Patients were telephoned 3 times a day during the first 3 days of the study and then once daily for the remainder of the study to determine if there were any signs of opiate overdose or withdrawal. The patient was to be followed as medically indicated based on the responses to the questions. Safety assessments included summarizing the incidences of adverse events (including topical adverse events), vital signs measurements, and clinical laboratory evaluations. Blood samples were also collected for analysis of naltrexone and fentanyl concentrations at scheduled times during the study. Efficacy assessments included patient global assessments, investigator global assessments, pain intensity, and brief pain inventory. Blood samples were also to be collected for analysis of naltrexone and fentanyl prior to any dose change and if a patient experienced a serious adverse event possibly or probably related to study drug. Duragesic delivering fentanyl doses of 25 mcg/h, 50 mcg/h, 75 mcg/h, or 100 mcg/h, and a D-TRANS placebo on Days 1, 4, 7, 10, and 13 or D-TRANS fentanyl with naltrexone delivering fentanyl doses of 25 mcg/h, 50 mcg/h, 75 mcg/h, or 100 mcg/h, and a placebo.
PURPOSE: To provide a drug, comprising a toxin extracted from the ovary of a globefish as an active ingredient and effectively usable for a biochemical reagent used in genetic engineering, a therapeutic agent for arrhythmia, an analgesic agent, an insecticide, etc. CONSTITUTION: The ovary of a globefish is dipped in a liquid to extract a toxin in the ovary into the liquid. The extracted toxin is then centrifuged and subsequently filtered to remove an unrequired solid. Thereby, a primary supernatant is obtained and heated at 80 deg.C to coagulate proteins until an albumenlike state of an egg attains. The heated material is filtered to remove the proteins. A secondary supernatant is prepared and permeated through a filter to trap the toxin in the filter. The filter trapping the toxin is then washed with an acetic acid solution to produce the acetic acid solution containing the toxin. The resultant solution is regulated to a weakly alkaline state to precipitate and recover the toxin.
PURPOSE:To obtain the titled cosmetic by mixing ethanol with a powdery cosmetic base composed of a powder for cosmetic, an ethanol-insoluble lubricant selected from hydrocarbon oils and silicone oils and a surfactant and filling the resultant slurry in a container. CONSTITUTION:The titled cosmetic having excellent impact resistance is produced by mixing ethanol with a powdery cosmetic base composed of 75-95wt.%of powder for cosmetic (e.g. talc, titanium oxide or nylon powder), 5-20wt.% of an ethanol-insoluble lubricant selected from hydrocarbon oils and silicone oils (e.g. liquid paraffin or dimethylpolysiloxane) and <=5wt.% of a surfactant (e.g. sorbitan sesquioleate), filling the obtained slurry in a container and removing ethanol e.g. by spontaneous drying. The cosmetic has extremely excellent molded state, is free from caking property, keeps excellent application feeling until the cosmetic is completely consumed and is resistant to cracking and falling-off.
BACKGROUND: To date, the relationship between the Transesophageal Echocardiography (TEE) monitoring indicator tricuspid annular plane systolic excursion (TAPSE) and the incidence of postoperative acute kidney injury (AKI) in Coronary Artery Bypass Grafting(CABG) patients remains unknown. The main objective of this study was to explore the relationship between the TAPSE and the incidence of AKI in CABG patients.
METHODS: This was a multicenter prospective cohort study was conducted between September 2021 and July 2022. Among 266 patients aged at least 18 years who underwent elective CABG, 140 were included.
RESULTS: We measured TAPSE via M-mode TEE via the mid-esophageal (ME) right ventricle(RV) inflow-outflow view (60°). All echocardiographic measurements were performed three separate times at each time point: T0 (before the start of CABG), T2 (approximately 5 ∼ 10 min after neutralization of protamine) and T3 (before leaving the operating room), and then averaged. Serum creatinine was measured 1 day before and within 7 days after CABG. There was no statistically significant association between the TEE-monitoring indicator TAPSE and the incidence of postoperative AKI in patients who underwent CABG.
CONCLUSIONS: The TAPSE was not significantly correlated with postoperative AKI incidence and could not predict the early occurrence of postoperative AKI in CABG patients. TEE needs more evaluation for clinical efficacy of predicting the early occurrence of postoperative AKI in isolated CABG.
The palliative care approach first emerged in the 11th century as a religious-based volunteer movement for the treatment of people suffering from terminal illnesses during long journeys. Although the quality of patient care changes all over the world, there is definitely a section in care that includes the responsibilities of the family. It is stated in the literature that the anxiety levels of the patient and family members who receive the necessary information and support about the disease decrease. The caregiving process is a very stressful situation for the caregiver, which can lead to physical and psychological problems. Anxiety levels of caregivers also increase due to the caregiving process that creates excessive stress and anxiety. Studies in which caregivers have high levels of anxiety due to the burden of care come to the fore in the literature. Mandala provides calming and relaxation as your mind. It silences the negative and complex emotions that bother the person himself. With the relaxation it provides, it allows the individual to listen to himself and to rest spiritually. Mandala allows to see holistically. While increasing one's awareness, it reveals what is hidden in the unconscious. Art therapy helps individuals feel themselves at the center of their lives, express themselves and discover who they are in the group while drawing, painting or making mandalas.

Jung stated that he created mandalas in times of distress when both he and his patients felt negative emotions. İn the previous studies; Mandala art therapy has been used to define psychiatric problems in children, to reduce stress and to calm down, to provide concentration and psychological relaxation, and positive results have been obtained.
A partially-automated life insurance settlement system and method is provided for processing and preparing life insurance settlement transaction documents, back-office requirement order management, user hierarchy network management, funding source presentation, offer negotiation and life insurance settlement transaction management. A data management device is interconnected with a plurality of terminals to permit data to be entered and retrieved from the data management device. The data management device is also provided with the capability of merging entered or stored data with life insurance settlement transaction documents. These documents are then transmitted for electronic signature or to be printed, signed, digitized and uploaded. Signed documents are then processed by a back-office to gather additional documents. Funder source presentation, distribution, inventory and offer management capabilities then manage pricing and offer steps of a transaction.
Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
RI is associated with poor prognosis and short median survival (32 months vs 55 months for MM patients with normal renal function). Thus, RI remains a major challenge for hematologists, including decisions on optimal anti-myeloma therapy, potential dialysis, supportive care and quality of life. The combination of a proteasome inhibitor and an immunomodulator is the preferred induction treatment for newly diagnosed transplant-eligible MM patients. After induction, high-dose therapy with Autologous Stem Cell Transplant (ASCT) is the standard of care for these patients. However, concerns related to management of comorbidities and treatment side effects question about therapeutic options for patients with severe renal damage. Of interest, recent studies argued that high-dose therapy followed by ASCT could be a feasible and safe method for renal failure MM patients. Yet, these observations on small sample size patients groups need to be confirmed with standardized conditions. This study proposes to evaluate the efficacy and the safety of this therapeutic strategy in MM patients with severe renal impairment.
The present disclosure provides a composition, which is an ophthalmic composition. The composition includes a moisturizing agent, a cooling agent, and an eye care component. The moisturizing agent includes polyethylene glycol-40 hydrogenated castor oil and polyethylene glycol-400. The cooling agent includes 2-isopropyl-N,2,3-trimethylbutyramide. The eye care component includes omega-3 fatty acid. Therefore, the composition of the present disclosure can provide good and long-lasting moisturizing effect by including polyethylene glycol-40 hydrogenated castor oil and polyethylene glycol-400, and provide good eye relief by including 2-isopropyl-N,2,3-trimethylbutyramide. Furthermore, the composition can provide good anti-dry eye and eye protection effect by including omega-3 fatty acid.
The present invention provides a Chinese medicine preparation for treating apoplexy, which is scientifically prepared from 13 kinds of traditional Chinese medicines including red ginseng, notoginseng, Chinese angelica root, spatholobus stem, red sage root, safflower, ginkgo leaves, haw, chrysanthemum, abalone shell, fleece-flower root, grassleaved sweetflag rhizomea and pueraria root according to the theory of traditional Chinese medicine and pharmacy. The present invention has the production method that the 13 kinds of traditional Chinese medicines are extracted by alcohol, water, etc. to be made into capsules or granules, oral liquid and tablets according to the modern pharmaceutical production process. The present invention has the efficiency of supplementing qi and activating blood circulation, dispersing blood stasis and dredging meridians, calming wind and eliminating phlegm for resuscitation. The present invention can also have the efficiency of inhibiting and eliminating atherosclerosis, inhibiting high cholesterin and hyperlipemia, promoting blood circulation, dissolving thrombus, resisting brain blood vessel ageing, etc. The present invention is mainly used for treating ischemic apoplexy (cerebral infarction), qi deficiency and blood stasis symptoms of apoplexy involving both collateral and meridian in a restoration stage and meridian occlusion caused by wind phlegm and blood stasis, and can also be used for the early stage of the acute stage of ischemic apoplexy. The present invention has the advantages of conspicuous curative effect, broad disease spectrum and radical treatment.
Prepns. to improve the digestive processes of domestic animals based on the contents of the rumen of ruminants are obtd. by filtering and pressing the rumen content immediately after slaughter. The resulting sludge is opt. stored at a suitable temp. for a predetermined time in anaerobic conditions. Subsequently a protective colloid, pref. dried milk powder is added in amts. of 8-12 wt% based on the solids content of the sludge, and at least 0.1 wt% antioxidant. The mixt. is homogenised and dried to a solids content of 92-94 wt%. Surface protecting and dispersing agents are added to the dry material and the prod. is packaged. - The fibrous content of the rumen is comminuted to a fibre length of at least 1-2 cm, the material is homogenised with at least 0.1 vol% antioxidant and dried to a solids content of at least 90 wt%. The resulting prod. is granulated and/or pressed into cake.
PURPOSE:To provide a new compound having activity against retrovirus such as Rous sarcoma virus, useful as an antiviral agent etc. CONSTITUTION:The objective compound of formula I (R1 is H, OH, amino, halogen or alkoxy; R2 is H or amino; R3 is H or alcohol-protecting group), e.g. cis-9-(2-hydroxymethylcyclopentyl)adenine. The compound of the formula I can be obtained by reaction of a compound of formula II with a compound of formula III (Ra is H, acetyl, alcohol-protecting group, etc.; Rb is H, acetyl, etc.) in the presence of a coupling reagent followed by deprotection.